Although we cannot make any consideration about the variants identified in ovarian cancer, having only analyzed four patients with ovarian cancer and two with breast and ovarian cancer, the detection of pathogenic variants in RAD51C and ATM is in agreement with what is reported in a case-control study performed on 2051 women with ovarian cancer. This evidence concerns the gene RAD51C and ovarian cancer.